Gérard, Alexandre O.
Merino, Diane
Van Obberghen, Elise K.
Rocher, Fanny
Destere, Alexandre
Lantéri-Minet, Michel
Drici, Milou-Daniel
Article History
Received: 26 March 2022
Accepted: 27 April 2022
First Online: 3 May 2022
Declarations
:
: Ethics committee approval was not required for this observational study because the analysis was carried out on an anonymized pharmacovigilance database.
: Not applicable.
: ML-M reports personal fee for advisory boards, speaker panels or investigation studies from Allergan, Amgen, Astellas, ATI, BMS, Boehringer, Boston Scientific, CoLucid, Convergence, GlaxoSmithKline, Grunenthal, Lilly, Lundbeck, Medtronic, MSD, Novartis, Pfizer, ReckittBenckiser, Saint-Jude, Sanofi-Aventis, Teva, UCB, UPSA and Zambon.All other authors do declare no competing interest.